Ligand Pharmaceuticals, Inc.
Company Overview
Ligand Pharmaceuticals Incorporated focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae. The company also offers Rylaze, a recombinant erwinia asparaginase, and Nexterone, a captisol-enabled formulation of amiod
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $51.81m | $49.41m | - | $741000.0 | 0.00% | 1.50% |
| June 30, 2024 | $41.53m | $61.9m | - | $1.27m | 0.00% | 2.05% |
| March 31, 2024 | $30.98m | $28.13m | - | $141000.0 | 0.00% | 0.50% |
Company Impact
Help us evaluate Ligand Pharmaceuticals, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.